Vialwirebiotech, curated
October 2, 2026, 6:55 AM
June 12, 2026
- 5:46 AM · Pharmaceutical Technology5:46 AMChina’s NMPA approves Akeso’s gumokimab for plaque psoriasis — Pharmaceutical Technology
- 5:00 AM · MIT Technology Review5:00 AMWhy “reprogramming” is the buzziest approach to reversing aging right now — MIT Technology Review
- 4:39 AM · Pharmaceutical Technology4:39 AMFDA grants priority review for Roche’s Tecentriq combo sBLA — Pharmaceutical Technology
June 11, 2026
- 9:04 PM · TechCrunch
- 5:15 PM · SCMP — Tech5:15 PMBiotech firm WuXi sues US over allegations it supports China’s military — SCMP — Tech
- 2:33 PM · STAT News2:33 PMNonprofit buys experimental cancer drug to maintain patient access — STAT News
- 1:06 PM · STAT News1:06 PMSTAT+: Abridge inks deals with Nvidia and Lilly — STAT News
- 12:00 PM · BioWorld12:00 PMEnliven’s phase I CML data Enable phase III with BCR/ABL1 bid — BioWorld
- 12:00 PM · BioWorld12:00 PMAnother FDA no for Camurus’ monthly acromegaly drug Oclaiz — BioWorld
- 12:00 PM · BioWorld12:00 PMDermasensor receives CE mark for skin cancer detection device — BioWorld
- 11:57 AM · Bloomberg — Technology11:57 AMNovo Detects Unauthorized Access to Some Internal IT Systems — Bloomberg — Technology
- 11:55 AM · BioPharma Dive11:55 AMSummit pulls $500M share sale a day after announcing it — BioPharma Dive
- 11:29 AM · BioPharma Dive11:29 AMSensorion, citing Regeneron competition, shifts focus to a different hearing loss therapy — BioPharma Dive
- 11:00 AM · BBC — Health11:00 AMWegovy weight-loss pill approved in UK — BBC — Health
- 10:18 AM · BioPharma Dive10:18 AMNovartis RNA drug acquired in $12B Avidity deal notches a trial win — BioPharma Dive
- 9:54 AM · Drug Discovery World9:54 AMDaltonTx launches AI drug discovery platform — Drug Discovery World
- 9:27 AM · BioPharma Dive9:27 AMJ&J looks to widen Imaavy’s use; $300M backs rare disease drug launch — BioPharma Dive
- 9:00 AM · BioWorld9:00 AMEthyreal Bio launches with focus on thyroid diseases — BioWorld
- 9:00 AM · BioWorld9:00 AMT-Curx gains trial clearance for Siglec-6-targeted TCX-001 — BioWorld
- 9:00 AM · BioWorld9:00 AMScenic Biotech joins MJFF LITE program to expand PLA2G15 research — BioWorld
- 8:05 AM · STAT News8:05 AMSTAT+: Enliven Therapeutics’ leukemia drug shows promise in new study — STAT News
- 6:24 AM · Drug Discovery World6:24 AMBead BioPharma emerges from stealth with novel drug platform — Drug Discovery World
- 5:35 AM · Pharmaceutical Technology5:35 AMXtalPi enters $400m partnership for small molecule therapy for GPCR target — Pharmaceutical Technology
- 5:35 AM · Pharmaceutical Technology5:35 AMBeren pockets $300m to take Niemann-Pick disease therapy to market — Pharmaceutical Technology
- 3:56 AM · Pharmaceutical Technology3:56 AMEMA validates Bayer’s asundexian application for ischaemic stroke — Pharmaceutical Technology
June 10, 2026
- 12:00 PM · BioWorld12:00 PMParabilis takes top spot, pricing largest biopharma IPO at $670M — BioWorld
- 12:00 PM · BioWorld12:00 PMEurope’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis — BioWorld
- 11:28 AM · BioPharma Dive11:28 AMSanofi stops immune drug trial in latest research setback — BioPharma Dive
- 11:21 AM · Pharmaceutical Executive11:21 AM<![CDATA[FDA Clears Every-8-Week Lebrikizumab Maintenance Dosing in Atopic Dermatitis]]> — Pharmaceutical Executive
- 10:47 AM · Drug Discovery World10:47 AMGLP-1 reduces liver fat by 63%, trial results show — Drug Discovery World
- 9:12 AM · BioPharma Dive9:12 AMAstraZeneca’s ‘extensive’ obesity drug push; $125M for ultrasound-aided genetic medicine — BioPharma Dive
- 9:00 AM · BioWorld9:00 AMAntengene’s ATG-201 gains IND clearance in China — BioWorld
- 9:00 AM · BioWorld9:00 AMSensorion selects SENS-601 as lead program for hearing loss — BioWorld
- 9:00 AM · BioWorld9:00 AMSyntax Bio and Mayo Clinic partner in type 1 diabetes — BioWorld
- 9:00 AM · BioWorld9:00 AMPhoremost unveils PMC-001 as lead program — BioWorld